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Abstract
Background: Type 2 diabetes is a major epidemic in the United States, with an estimated 23.6 million
diabetics or 7.8% of the population according to the National Diabetic Information Clearinghouse.
Obstructive Sleep Apnea is also a major epidemic affecting 4-17% of the population. Each of these disorders,
independently, can lead to increased morbidity and mortality. Rapidly developing research suggests these
disorders share many important factors that must be investigated further.
Purpose of Study: To determine if continuous positive airway pressure (CPAP) will improve glucose control
and insulin sensitivity in diabetic patients with Obstructive Sleep Apnea (OSA).
Hypothesis: Studies have shown sympathetic activation with hypoxic episodes in sleep apnea. In addition,
sleep loss has been shown to alter glucose tolerance and possibly increases insulin resistance. Will CPAP
prevent hypoxic episodes thereby stopping the sympathetic activation during sleep and improve resistance
and tolerance?
Study Design/Methods: Exhaustive search of available medical literature using the following search engines;
Medline, Pub Med, EBMRM, CINAHL and MDconsult. The study must have been published in English and
contain the following search terms; Type 2 diabetes, obstructive sleep apnea and CPAP. Due to the rapid
release if research data in this area, the search was also limited to studies published in the last six years.
Results: Obstructive Sleep Apnea and type 2 diabetes have long shared one common denominator, obesity.
The five studies included in this systematic review attempted to limit discussion to factors that may suggest a
causal relationship between these two disorders. There was only one study that offered a randomized, double-
blinded, placebo controlled study by using a sham CPAP machine and was able to weigh the results
independently against a control group and subsequently raise important questions regarding the other studies.
The four other studies all reported significant positive results in glycemic and insulin control when
implementing CPAP. They were single arm, single center non randomized prospective studies.
Conclusion: Many cardiovascular, metabolic, endocrinological, and neurovascular variables exist that would
slow or inhibit a prompt response to a therapy. Other authors noted conflicting results could be attributed to
differences in sample sizes, duration of study, lack of objective adherence to data and possible changes in body
composition. Only one study suggest there is no causal or therapeutic relationship between these two
disorders and therefore treating OSA with CPAP will not independently affect diabetic outcomes. Previous
research presented strong conclusions suggesting such a relationship however were weak in study design.
Intuitively it seems that activation of the sympathetic nervous system and sleep loss would affect diabetic
control however this was not reliably proven in these studies. Given the equivocal results it would be too early
for the clinician to modify treatment in reliance on research to date although this area of study has some
promise and further research might reveal some more definitive answers in the future.
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Abstract   
 
Background:  Type 2 diabetes is a major epidemic in the United States, with an estimated 23.6 million 
diabetics or 7.8% of the population according to the National Diabetic Information Clearinghouse. 
Obstructive Sleep Apnea is also a major epidemic affecting 4-17% of the population.  Each of these 
disorders, independently, can lead to increased morbidity and mortality. Rapidly developing research 
suggests these disorders share many important factors that must be investigated further. 
Purpose of Study: To determine if continuous positive airway pressure (CPAP) will improve glucose 
control and insulin sensitivity in diabetic patients with Obstructive Sleep Apnea (OSA).  Hypothesis: 
Studies have shown sympathetic activation with hypoxic episodes in sleep apnea. In addition, sleep 
loss has been shown to alter glucose tolerance and possibly increases insulin resistance.  Will CPAP 
prevent hypoxic episodes thereby stopping the sympathetic activation during sleep and improve 
resistance and tolerance?  Study Design/Methods:  Exhaustive search of available medical literature 
using the following search engines; Medline, Pub Med, EBMRM, CINAHL and MDconsult.  The 
study must have been published in English and contain the following search terms; Type 2 diabetes, 
obstructive sleep apnea and CPAP.  Due to the rapid release if research data in this area, the search was 
also limited to studies published in the last six years.  Results: Obstructive Sleep Apnea and type 2 
diabetes have long shared one common denominator, obesity.  The five studies included in this 
systematic review attempted to limit discussion to factors that may suggest a causal relationship 
between these two disorders.  There was only one study that offered a randomized, double-blinded, 
placebo controlled study by using a sham CPAP machine and was able to weigh the results 
independently against a control group and subsequently raise important questions regarding the other 
studies.  The four other studies all reported significant positive results in glycemic and insulin control 
when implementing CPAP.  They were single arm, single center non randomized prospective studies.  
Conclusion: Many cardiovascular, metabolic, endocrinological, and neurovascular variables exist that 
would slow or inhibit a prompt response to a therapy.  Other authors noted conflicting results could be 
attributed to differences in sample sizes, duration of study, lack of objective adherence to data and 
possible changes in body composition.  Only one study suggest there is no causal or therapeutic 
relationship between these two disorders and therefore treating OSA with CPAP will not 
independently affect diabetic outcomes.  Previous research presented strong conclusions suggesting 
such a relationship however were weak in study design.  Intuitively it seems that activation of the 
sympathetic nervous system and sleep loss would affect diabetic control however this was not reliably 
proven in these studies.  Given the equivocal results it would be too early for the clinician to modify 
treatment in reliance on research to date although this area of study has some promise and further 
research might reveal some more definitive answers in the future.   
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The Effects of Continuous Positive Airway Pressure in Type 2 Diabetic Patients with           
Newly Diagnosed Obstructive Sleep Apnea 
 
Introduction 
According to the National Diabetic Information Clearinghouse , type 2 diabetes is a major 
epidemic in the United States with an estimated 23.6 million diabetics or 7.8% of the population.  The 
National Sleep Foundation credits Obstructive Sleep Apnea (OSA) with epidemic status affecting over 
18 million Americans.  In addition an estimated 93% of women and 82% of men with obstructive sleep 
apnea have not been diagnosed.1   Interestingly, a reported 46% of commercial truck drivers and 14% 
of professional football players suffer from obstructive sleep apnea.2  Each of these disorders, 
independently, can lead to increased morbidity and mortality, however rapidly developing research 
suggests these disorders share many important factors that must be investigated further.   
 
“Sleep apnea is a general term encompassing two distinct entities”, central sleep apnea and 
obstructive sleep apnea (OSA).  Central sleep apnea is a rare disorder where there is abnormal 
neurological control of the diaphragm during sleep which causes decreased respiratory effort.2  
Obstructive apnea is defined as the total cessation of airflow for 10 seconds or more despite continued 
ventilator effort.  These episodes are associated with a decrease in oxygen saturation of 4% or more.  
Patients suffering five or more such apneas per hour are considered to have OSA and may see a 
decrease in oxygen saturation of 30% to 50% in cessation of airflow for 10 seconds or longer.2  
 
Maximum prevalence of OSA occurs between the fifth and seventh decade of life.  OSA 
“affects more than 10% of the population over 65 years of age and more men than woman.” 2  Young 
men are two times more likely than women of the same age to develop sleep apnea 3 however, as 
women go through menopause the numbers converge. Young et al reported the risk for 
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apnea/hypoapnea events (AHI) more than doubles after menopause.1  Pashayan and colleagues 
reported a randomized placebo controlled study in which elderly men received intramuscular 
testosterone.  The participants noted shortened sleep and increased sleep apnea. Studies in women 
revealed worsening sleep apnea after menopause which resolved with hormone replacement.2 
 
The association between OSA and diabetes cannot be ignored.  In a report by West et al. the 
prevalence of OSA in diabetic men was estimated at 23%.  Data from both epidemiologic and clinical 
studies suggest OSA is an independent risk factor for type 2 diabetes and some authors even suggest a 
“reverse directions of causality”, meaning diabetes may be causing breathing abnormalities during 
sleep.4  Furthermore, OSA is believed to lead to chronic stress caused by recurrent hypoxia and 
cerebral arousals.  “Theses adverse physiologic effects may trigger downstream mechanisms that 
promote insulin resistance or glucose tolerance.” 5 
 
Sleep fragmentation and loss, dysregulation of the hypothalamic-pituitary axis, endothelial 
dysfunction, elevated sympathetic nervous system activity and increase in cytokine and adipokine 
release primarily from adipose tissue, have all been implicated as potential mechanisms for insulin 
resistance and glucose tolerance in OSA patients. 3, 5, 6  
 
Sleep fragmentation and loss leads to impaired glucose tolerance which prolongs glucose 
clearance, a major factor in the development of type 2 diabetes.4  Surveys from the National Sleep 
Foundation have documented self reported sleep duration of Americans has decreased by 1.5-2 hours 
over the past 40 years.  Young adults who reported they sleep less than 7 hours per night, “increased 
from 16% in 1960 to 37% in 2002”. 5 In addition, another study found that “after 2 days of sleep 
curtailment lead to higher glucose levels, lower insulin levels, and a 30% increase in appetite for high 
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caloric density carbohydrates”.  Furthermore Ghrelin, a stomach-derived peptide that stimulates 
appetite, increased by 28%.5 
 
Elevated sympathetic nervous system activity leads to an increase in gluconeogenesis, 
lypolysis, muscle glucogen breakdown and oxidative stress which are collectively factors for the onset 
of diabetes.4, 5  In addition, repeated activation of the sympathetic system and subsequent release of 
epinephrine and norepinephrine can change the vagal response to deoxygination leading to worsening 
pre-existing coronary artery disease.  Activating the sympathetic nervous system in someone with 
coronary vascular disease can lead to increased cardiac afterload, myocardial work and oxygen 
demand.2 
 
Many studies have found elevated tumor necrosis factor-alpha and interleukin-6 which are 
powerful cytokines in OSA that oppose the function of insulin.5  Adipose tissue, and particularly 
abdominal fat, is a “rich source of adipokines and cytokines” that influence insulin sensitivity.  
Obstructive sleep apnea “may modulate the expression and secretion of the inflammatory mediators 
from fat and other tissue.” A review of MRI scans found a correlation between OSA and subcutaneous 
and intra-abdominal fat.5  This study reported no correlation with subcutaneous fat in the neck or 
parapharyngeal region.3  
 
The purpose of this study is to determine if CPAP will improve glucose control and insulin 
sensitivity in diabetic patients with obstructive sleep apnea.  Previous studies have shown sympathetic 
activation with hypoxic episodes in sleep apnea.  Moreover, sleep loss has been shown to alter glucose 
tolerance and increase insulin resistance. The hypothesis is that CPAP will prevent hypoxic episodes 
significantly decreasing sympathetic activity during sleep and thereby improving resistance and 
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tolerance.  Proper diagnosis and treatment of OSA in diabetic patients may improve glucose control 
and subsequently reduce morbidity and mortality for millions of Americans.   
 
 In spite of ongoing research into this specific area of study, some of the terms used in the field 
are less than familiar to those not considered to be specialists.  Accordingly a brief but specific 
introduction to some of these terms is included to facilitate understanding. 
 
Adiponectin-  Most common protein secreted by adipocytes.  Adiponectin is decreased in 
obesity and insulin resistance and there is a close association between hypoadiponectinemia, 
insulin resistance and hyperinsulinemia.  Adiponectin expression increases with improved 
insulin sensitivity and weight loss.7  
 
 Actigraphy-  Objective exam to determine daytime sleepiness. A small wrist mounted device 
records activity throughout the day over a one to three week period.  The activity is then 
compared to the wake/sleep pattern data from a polysomnograph.8  
 
Epworth Sleepiness Score (ESS)- used to subjectively screen patients to identify excessive 
daytime sleepiness by completing a questionnaire.  Points range between 0-24 and a score 
higher than 11 suggests a high probability of a sleep problem.8  (See Table 3) 
 
Polysomnography- determines states of sleep by recording EMG, EEG and REM. If apneic 
episodes are detected, then airflow, chest movement, SaO2 and CO2 monitors are used.8  In 
adult OSA, a patient must demonstrate at least five obstructive apneas per one hour of sleep 
(Apnea, hypoapnea Index or AHI), each lasting at least 10 seconds and associated with at least 
one of the following; frequent arousals from sleep, bradytachycardia or oxygen desaturation.3  
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Apnea, Hypoapnea Index (AHI)- measures the frequency and duration of apneas per hour 
during a polysomnogram. 
 
Continuous Glucose Monitoring System (CGMS)- records data from a subcutaneous sensor 
every 5 minutes for 72 hours.  This provides a continuous profile of glucose levels in the tissue 
which lag about 13 minutes behind serum glucose levels.3  
 
Euglycaemic Hyperinsulinaemic Clamp- A type of CGMS. Babu et al9 reported when 
correlated with serum glucose has an accuracy of 96.2%.9 
 
Homeostatic Model Assessment (HOMA)-  computer and mathematical method to quantify 
insulin resistance.10  General equation (glucose mg/dL x insulin mU/mL)/405.   
 
Glycosylated Hemoglobin (Hemoglobin A1c, HbA1c)- Red blood cells are exposed to glucose 
and become glycosylated without the help of an enzyme, at a rate that is directly proportional to 
the glucose concentration during the life span of the RBC.  Measurements can estimate the 
average plasma glucose during the last 120 days. 11 
 
Methods 
An exhaustive literature search using Medline, Pub Med, EBMRM, MDconsult and CINAHL 
was conducted using diabetes, sleep apnea and CPAP as search terms.  Articles were limited to the 
English language and to those published in the last 6 years. This is a relatively short time frame 
however there is a significant amount of research in this area with many new studies annually.  Only 
articles that look at the effects of CPAP on type 2 diabetes were included.  (Table 1) 
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Results 
 
Five studies were included in this review. One randomized controlled, double-blinded trial and 
four single center, single arm, non-randomized trials. (See Table 2)  
 
Harsch et al12 attempted to determine if OSA is an independent risk factor for increased insulin 
resistance in diabetics.  Nine diabetics were selected, placed on CPAP, and insulin sensitivity index 
(ISI) was measured at 2 days and at 3 months.  The patients included 7 males and 2 postmenopausal 
females with type 2 diabetes and OSA with a mean age of 56.3 years.  They noted the mean HbA1c of 
their population was 6.4% which is significantly lower than most of the previous studies.  Patients with 
severe co-morbid conditions such as; malignancies, liver disease and other endocrine disorders were 
excluded.  In addition, TSH and insulin like growth factor-I had to be within normal limits.  Patients 
with hyperlipidemia and hypertension as well as those treated with calcium channel blockers and ACE 
inhibitors were included. Patients treated with beta-blockers or steroids were excluded.12   
 
Insulin responsiveness was measured by a hyperinsulinaemic euglycaemic clamp which is 
considered the gold standard in sensitivity measurement.12  CPAP compliance was documented by 
built in data stores and was downloaded after every 47 days of use.  In addition, patients underwent an 
investigation for peripheral and autonomic diabetic neuropathy due to its documented relationship with 
sleep disordered breathing.12 
 
The results found ISI was unchanged after two days but significantly improved after 3 months 
(47%).  Hemaglobin A1c however was not affected.  Harsch et al 12 reported these results varied from 
their earlier study in which they looked at ISI after the same treatment in 40 non diabetics with OSA.  
In the non diabetic group there was rapid and significant improvement in insulin sensitivity even after 
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2 days of therapy.  They noted there was no significant difference in age or BMI between the 9 diabetic 
patients and the 40 non-diabetic patients.  Harsch et al12 attributed these different findings to the “fixed 
and genetically determined degree of insulin resistance, which is thus more difficult to reverse in 
diabetic than non-diabetic patients”.   
 
They also speculated that 4 of 9 of the diabetic patients were on Metformin therapy which had 
made them more responsive to improving insulin sensitivity. This is the only study to provide data on 
which anti-diabetic medications patients were taking.  In their diabetic study they reported good CPAP 
compliance with a mean usage of 5.8 hrs/night.  In addition, one patient lost 21kg during the study and 
no longer required medication, otherwise there was no significant change in BMI.  
 
Babu et al9 produced the most substantial positive findings with their study assessing the effects 
of CPAP treatment in SDB on glycemic control in a group of obese patients with type 2 diabetes.  
Their subjects were diabetic patients who met the clinical criteria for OSA.  This study focused on 
patients with hemoglobin A1c greater than 7% but did not exclude those with a lower HbA1c.  Forty-
two were enrolled after meeting the inclusion criteria and 25 were available for final analysis with all 
“lost” patients accounted for.9   
 
The patients had a mean age of 50.7 years, 16 were men, a mean baseline HbA1c was 8.3% and 
the mean BMI was 42.7.  Twenty-four of the twenty-five patients used machines that allowed for 
adherence monitoring.  The group underwent baseline glucose, HbA1c and 72-hour continuous glucose 
monitoring with ongoing maintenance of a food diary before CPAP initiation which was unique to this 
study.  The subjects were scheduled to return between 30-90 days for repeat polysomnography and 72 
hour/food diary testing.  Compliance of CPAP was considered four hours or more per night.9 
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The results were significant.  Mean CPAP treatment was 83 days. Mean 1 hour postprandial 
glucose values were significantly reduced for breakfast  (191mg/dL to 130mg/dL) lunch (196 mg/dL to 
138 mg/dL) and dinner (199 mg/dL to 137 mg/dL).  In 17 patients with HbA1c greater than 7%, 
HbA1c was reduced by a mean 9.2% to 8.6%.  Further analysis of this sub group revealed a significant 
decrease in total number of serum glucose readings of 200 mg/dL or greater with a mean reduction 
from 148 to 83 after CPAP.  There was no statistically significant reduction in the 8 with HbA1c less 
than 7%.  This was the only study that found a reduction in HbA1c of statistical significance.9 
 
West et al10 posted the first randomized double blinded trial and also the only to report findings 
not in support of the proposition that CPAP improves glucose control and insulin sensitivity.  Patients 
were type 2 male diabetics, referred to a sleep clinic between June 2004 and August 2005, who had not 
yet initiated CPAP therapy for their newly diagnosed OSA.  Patients were excluded if they required 
“urgent CPAP or had unstable diabetes”.  Forty-two patients were enrolled after meeting inclusion 
criteria.10   
 
Patients were randomized into a CPAP group and a placebo group.  The placebo group utilized 
the same machines which were set to the lowest setting with a flow restrictor and additional holes in 
the mask to prevent rebreathing.  Insulin resistance was measured using both the HOMA and 
hyperinsulinaemic euglycaemic clamp.  HbA1c, lipids, adiponectin, CRP, height, weight and BMI 
were recorded as well as neck, waist and hip measurements.  Body composition was measured using 
bioelectrical impedance analysis to determine if fat distribution was affected.  Subjective sleepiness 
was measured by the Epworth Sleepiness Score (ESS).  Objective sleepiness was measured by the 
Maintenance of Wakefulness test (MWT).  Duration of the study was 3 months.10 
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Twenty-one men were randomized to the CPAP group and 21 were randomized to the placebo 
group.  One patient from the CPAP group was found to have a defective machine that delivered 
minimal pressure so his data was transferred to the placebo group.  There were no significant 
differences between the groups in age, diabetic treatment and severity of OSA.  One patient was lost 
from the treatment group due to hospital admission for emergency cardiac surgery and 9 patients did 
not receive the second Euglycaemic clamp due to “technical difficulties”.10  
 
As expected, there was significant change in measures of daytime sleepiness with the 
therapeutic group.  There was a slight positive change in insulin sensitivity expressed as the quantity of 
glucose metabolized (M) per unit in plasma insulin concentration (I) with data from the Euglycaemic 
clamp. M/I had increased 1.7 in the therapeutic CPAP group compared to a decrease of 5.7 in the 
placebo group.  A positive change indicates improved sensitivity.  There was, however, no statistically 
significant change in the HOMA, Adiponectin, weight, BMI, waist to hip ratio, lipids or CRP.  Mean 
hours of CPAP use in the therapeutic group was 3.3 hours and 3.5 hours in the placebo group.10   
 
Dawson et al13 developed a study to focus on the short term effects of CPAP on glucose during 
sleep in diabetic patients with newly diagnosed OSA.  The interstitial glucose level was monitored 
during a polysomnogram and patients with an AHI greater than 15 were allowed to continue the study.  
CPAP was initiated for at least 3 more weeks with a mean use of 41 days, and then both the 
polysomnogram and interstitial glucose monitoring were repeated.  The primary end point was to 
determine the mean interstitial glucose for all 30 second recordings, during a complete 
polysomnogram, in addition to the calculating the mean 24 hour interstitial glucose and postprandial 
level after breakfast.13   
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The participants were required to use the CPAP a minimum of 4 hours a night and 3 ultimately 
were excluded from the study for non compliance.  Twenty eight subjects completed the first night of 
the study and 22 completed the second night with all the “lost” accounted for.  In addition, one 
participant was dropped after showing many central apneas and another because she was the only type 
1 diabetic in the study.13    
 
Eighteen had a BMI greater than 30 and ten were greater than 40.  Sixteen had severe sleep 
apnea and 8 diabetics had an HbA1c greater than 7%.  Twelve subjects gained weight between the 
studies with 6 gaining more than 2kg.  The mean sleeping glucose decreased from 122 mg/dL to 102.9 
mg/dL and the median standard deviation in glucose variance decreased from 20.0 mg/dL to 13.0 
mg/dL.  There were no significant changes in the mean daytime glucose from 0700 hours and 2300 
hours and HbA1c.  It was noted that while the mean number of days on CPAP was 41, there were only 
3 subjects who had 60 or more days of CPAP use.13 
 
Pallayova et al6 developed a very similar study, in which diabetics with newly diagnosed OSA, 
underwent several days of continuous interstitial glucose monitoring and then returned to a sleep clinic 
for CPAP titration and glucose monitoring.  Fourteen participants completed the study and the results 
were very similar to those in Dawson.  There were 25,304 continuous glucose measurements obtained, 
with 473 paired capillary glucose measurements for confirmation, and a total average of 150.5 hours of 
glucose monitoring per patient.  The results revealed a statistically significant decrease in mean 
nocturnal glycemia and glucose variability.6  
 
Discussion 
Obstructive Sleep Apnea and type 2 diabetes have long shared one common denominator, 
obesity.  The five studies included in this systematic review attempted to limit additional factors that 
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may suggest a causal relationship between these two disorders.  Unfortunately, there was only one well 
designed trial that offered a randomized, double-blinded, placebo controlled study.  West et al10 was 
the only group to use a sham CPAP machine and were able to weight the results independently against 
a control group and subsequently raise important questions regarding the other studies.  What are the 
behavioral influences on study results? 
 
 All studies used a continuous glucose monitoring system which is required to determine 
glucose variability, and both Harsch et al12 and West et al10 specifically identified the use of a 
Hyperinsulinaemic Euglycaemic Clamp. All studies except Pallayova took measures to ensure CPAP 
compliance which is a major issue with newly diagnosed OSA patients. 6, 9, 10, 12, 13  Harsch et al14, 
Babu et al9 and West et al10 all used machines that recorded usage data.  Dawson and colleagues used 
weekly follow-ups to ensure compliance but was also the most aggressive, excluding 3 participates 
who did not meet their 4 hour usage criterion.13  
 
West et al10 included the lowest compliance numbers with mean hours of use at 3.3 in the 
therapeutic group and 3.6 hours in the placebo group. They argue low compliance was not a significant 
factor since these hours also produced significant improvement in OSA and therefore should have 
decreased nocturnal sympathetic activity and glucose variations. Accordingly, they did not follow the 
example of Dawson in excluding participants not in compliance.10  
 
Study duration varied significantly both between studies and within them.  Babu’s patients 
varied CPAP usage ± 50 days from the mean of 83 days.9 Dawson et al13 had a range of 26 to 96 days 
and the range in the Pallayova et al6 study was unclear.  
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 Harsch et al14, Babu et al9, Dawson et al13 and Pallayova et al6 were all single-center, single-
arm, non-randomized, prospective studies with very similar inclusion and exclusion criteria and end-
points. The number of participants in the studies ranged from 9 in Harsch to 40 in West’s double 
armed study.14  BMI ranged from 36.6 in West et al to 42.7 in Babu et al. 9, 10  
 
No single study took significant steps to control or monitor diet.  Babu and his group perhaps 
put forth the best effort by asking their participants to complete a food diary when on the 72-hour 
continuous glucose monitoring.  They then were able to confirm the patients’ diet with glucose 
fluctuations in the glucose test data.  In addition they were the only group to look at postprandial 
results for all meals (0700-2200). 9  
 
West et al10 did not monitor diet but were the only study to monitor for changes in abdominal 
adiposity by measuring body composition. West and colleagues raised a very important concerns 
regarding their findings by questioning other studies positive results without improved, and in some 
cases, increased BMI.  When considering the effects of abdominal adiposity on glucose metabolism, 
they stated the results may have shown improvement due to “changes in body fat distribution” and not 
due to CPAP use.10  Moreover, it was noted that these changes would not have been reflected in a 
simple BMI measurement. 
 
This study also raises a very important argument when looking at continuous glucose 
monitoring.  Not only is it more likely people would  to modify their behavior either by medication 
compliance, food choices or CPAP compliance when they know they are being monitored, but the 
testing materials may also alter the results of the studies.  West et al10 noted hyerinsulinaemic 
euglycaemic clamp is an intense invasive procedure in which a probe in placed in the abdominal tissue. 
This procedure in and of itself would cause a significant amount of anxiety and increase sympathetic 
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activity.10  Over time, with repeat procedures, that anxiety would diminish.  West et al10 points out that, 
in studies without a control, a researcher may interpret these results as a positive finding for the 
intervention or therapy, as opposed to an incidental reaction to a specific event.  It is not clear if this 
occurred in the other studies including the Harsch et al14 study referred to by West et al. 10 
 
West et al10 noted, when treatment and placebo are compared, there was not a significant 
improvement in glucose tolerance when looking at the euglycemic clamp.10  Babu et al9 argued they 
compared their population with and without CPAP so they were controlled against themselves. Of 
course this design is not randomized, blinded or placebo controlled. 
 
HbA1C ranged from 6.4 in Harsch et al14 to 8.5 in West et al’s10 therapeutic group with Babu et 
al9 as the only study showing HbA1c improvement of statistical significance.  Harsch et al was the 
only study to significantly outline the current diabetic treatment for each participant and whether he or 
she was currently being treated with an insulin sensitizing medication such as metformin or 
thizolididones.14  When looking at this data however, the metformin patients did not improve 
significantly more than the others.  All of the studies used “stability of diabetic management” as an 
inclusion criteria, excluding patients recently put on new medications nor did they allow medication 
changes during the study period. 
 
Conclusion 
 The studies collected for this review share three common factors, obstructive sleep apnea, type 
2 diabetes and obesity.  When combining these three disorders and attempting to interpret the data a 
clinician must remain skeptical.  Many cardiovascular, metabolic, endocrinolocial, and neurovascular 
variables exist that would slow or inhibit a prompt response to a therapy. Tarsal et al4 noted conflicting 
results could be attributed to differences in sample sizes, duration of study, lack of objective adherence 
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to data and possible changes in body composition.4  West et al10 suggest there is no causal or 
therapeutic relationship between these disorders and that treating OSA with CPAP will not 
independently affect diabetic outcomes.10  The other studies presented strong conclusions suggesting 
the existence of such a relationship, however their efforts were weak in study design.   
 
Intuitively it seems activation of the sympathetic nervous system and sleep loss would affect 
diabetic control however this was not reliably proven in these studies.  Given the equivocal results it 
would be too early for the clinician to modify treatment in reliance on research to date although this 
area of study has some promise and further research might reveal more definitive answers in the future.   
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Table 1 Summary of Clinical Trials Reviewed 
Study Deign End Points Size 
(n=x) 
Duration Measurements Outcome Issues 
Harsch et 
al 
Single Centre, 
Single arm, non-
randomized, 
prospective 
study 
Is OSA and 
independent risk 
factor for insulin 
resistance in 
diabetics 
n=9 3 months ISI at baseline, after 2 
days, and after 3 months, 
BMI, HbA1c, Serum 
Leptin, Polysomnogram, 
ESS 
Significant 
improvement in 
insulin sensitivity 
after 3 months of 
CPAP use 
 
Babu et al Single Centre, 
Single arm, non-
randomized, 
prospective 
study 
Changes in 
interstitial 
glucose levels 
n=25 30 to 90 days of 
treatment 
72-hour continuous 
glucose monitoring, Food 
Diary, A1c, 
polysomnography 
Significant 
reduction in HbA1c 
No other study 
has been able 
to reproduce 
such dramatic 
results 
West et al Randomized, 
Double-blind 
Placebo-
controlled  
Effects of CPAP 
on insulin 
resistance 
n=40 3 months ESS, polysomnography, 
CGMS, HOMA, Body 
Composition, MWT, 
HbA1c, Lipids, CRP, 
Adiponectin 
No change in 
HbA1c, CGMS, 
Cody Composition, 
Lipids, CRP, 
Adiponectin 
Only study to 
use a placebo 
group, Only 
study not to 
find positive 
results. 7 
patients data 
was lost, 
unclear from 
which group. 
Dawson et 
al 
Single Centre, 
Single arm, non-
randomized, 
prospective 
study 
Measure 
interstitial 
glucose during 
two 
polysomnograms 
at baseline and 
after a mean of 
41 days 
n=20 26 to 96 days  Polysomnogram, HbA1c, 
CGMS 
Mean sleeping 
glucose and glucose 
variability 
decreased 
significantly 
No control 
group, Large 
variance in 
duration of 
CPAP before 
retesting, 
Many 
variables such 
as diet and  
medication. 
Pallayova 
et al 
Single Centre, 
Single arm, non-
randomized, 
prospective 
study 
Will CPAP 
prevent apnea-
related glucose 
fluctuations 
n=14 unknown CGMS, Polysmnography Significant 
reduction in glucose 
variability with the 
initiation of CPAP 
No control 
group 
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Table 2 Results of Clinical Trials Reviewed 
Harsch et al 
2004 
-Insulin sensitivity was unchanged after 2 days of CPAP but significantly improved 
after 3 months   
-HbA1c and BMI were unaffected   
-No correlation with Leptin levels 
Babu et al 
2005 
-Significant reduction of 1-hour postprandial glucose levels after 83 ±50 days of CPAP   
use  
-Significant reduction in HbA1c in patients with starting A1c > 7% after CPAP use  
West et al 
2007 
-No significant change in glycaemic control and insulin resistance in either therapeutic  
or placebo groups   
-BMI and body habitus were unchanged   
-No correlation between CPAP use and diabetic control  
-Improved Epworth Sleepiness Score in therapeutic group  
Dawson et al 
2008 
-Mean sleeping glucose and glucose variability levels decreased after CPAP use.   
-No significant change in HbA1c.  
Pallayova et 
al   2008 
-Significant reduction in glucose variability with the use of CPAP 
-No significant change in HbA1c 
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Table 3                                   Epworth Sleepiness Scale 
                How Likely are you to doze off or fall asleep in the following situations? 
                   Answer considering how you have felt over the past one to two weeks 
 
                                                  0 = Would never doze 
                                                  1 = Slight chance of dozing 
                                                  2 = Moderate change of dozing 
                                                  3 = High chance of dozing 
                                                                                                                Score 
1 Sitting and reading  
2 Watching TV  
3 Sitting inactive in a public place  
4 As a passenger in a car for an hour without breaks  
5 Lying down to rest in the afternoon when able  
6 Sitting and talking to someone  
7 Sitting quietly after a lunch without alcohol  
8 In a car while stopped for a few minutes in traffic  
                                                                                                   Total= _________ 
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